23 mar: Zealand Pharma A/S - optagelse til handel og officiel notering af..
23 mar: Topdanmarks beholdning af egne aktier er over 10 %
23-03-2017 14:00:00

Lundbeck and Otsuka’s brexpiprazole for adult patients with schizophrenia accepted for review by EMA

Relateret indhold
11 jan - 
Lundbeck indgår forlig med Teva i erstatningssag - cita..
08 jan - 
Mandagens aktier: Vestas løb med interessen efter opjus..
08 jan - 
Aktier/middag: Genmab fortsætter anden handelsuge i top
Relateret debat
16 jan - 
Tak for en fin gennemgang af denne 'hemmelige' aktie. E..
15 jan - 
@Baunsgaard Jeg kiggede lige hurtigt paa Lundbeck. Dere..
15 jan - 
@MatthewDK Tak for en fornuftig oversigt og et godt gri..

Valby, 2017-03-23 14:00 CET (GLOBE NEWSWIRE) --

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the European Medicines Agency (EMA) has accepted for review a Marketing Authorisation Application for brexpiprazole to treat schizophrenia in adults.

Brexpiprazole is a once-daily, second-generation (atypical) oral antipsychotic that was discovered by Otsuka and co-developed by Otsuka and Lundbeck. The mechanism of action for brexpiprazole in the treatment of schizophrenia is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. In addition, brexpiprazole exhibits high affinity (subnanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors[i].

The application is supported by data from five phase III placebo-controlled clinical trials in adult subjects with schizophrenia including two multinational, six-week, randomized trials and a 52-week randomized maintenance trial[ii],[iii],[iv].

The EMA is anticipated to complete its review in second quarter of 2018.

Schizophrenia is a chronic, severe and disabling brain condition. Typically, symptoms are first seen in adults younger than 30 years of age and include hearing voices, believing other people are reading their minds or controlling their thoughts, and being suspicious or withdrawn. In Europe, it is estimated that there are about 5 million people with schizophrenia, with a prevalence of 0.6-0.8%[v]

Brexpiprazole was approved by the U.S. Food and Drug Administration in July 2015 to treat patients with schizophrenia (as well as an adjunctive treatment of major depressive disorder (MDD)). Brexpiprazole was also approved in February 2017 by Health Canada for the treatment of schizophrenia. In both countries brexpiprazole is distributed and marketed under the brand name REXULTI®,TM.  If the EMA grants regulatory approval to brexpiprazole, the brand name of the product in the EU would be RXULTI®.

 

Contacts

Lundbeck

Mads Kronborg                                                                                    

Senior Director, Corporate Communication                                                 

Phone: +45 36 43 40 00                                    

E-mail: mavk@lundbeck.com                                                    

 

Otsuka, Europe

Alison Ross

Otsuka Pharmaceutical Europe Ltd.

aross@Otsuka-Europe.com

+44 7768337128

 

Otsuka, Japan

Jeffrey Gilbert

Otsuka Pharmaceutical Co, Ltd.

gilbert.jeffrey@otsuka.co.jp

+81 3 6361 7379, +81 80 8728 6039

 

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.3 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

 

About Otsuka

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: 'Otsuka people creating new products for better health worldwide.' Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.

The Otsuka group of companies employs approximately 45,000 people globally. Otsuka Pharmaceutical Europe’s 600 employees channel their passion and energy into ensuring that the latest science is converted into needed therapies for patients with mental health disorders; kidney, cardiovascular, gastrointestinal and infectious diseases; and blood related cancers.

Our stories all start by taking the road less travelled. Learn more here:

www.otsuka.co.jp/en/ <http://www.otsuka.co.jp/en/> (Global)

www.otsuka-europe.com <http://www.otsuka-europe.com> (Europe)

 

References

i Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014b;350(3):589–604.

ii Correll, C., Skuban, A, Ouyang, J., et al. Efficacy and safety of Brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172:870–880; doi: 10.1176/appi.ajp.2015.14101275

iii Kane J. a, Skuban A., Ouyang J. et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophrenia Research 164 (2015) 127–135

iv Fleischhacker, W., Hobart, M., Ouyang J., et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: A randomized, double-blind, placebo-controlled study. Int. Journal of Neuropsychopharmacology (2017) 20(1) :11-21

v C. Altamura, A. Fagiolini, S. Galderisi, P. Rocca, A. Rossi. Schizophrenia today: epidemiology, diagnosis, course and models of care. Journal of Psychopathology 2014;20:223-243.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
15 jan
LUN
Det kan undre, at der ikke er mere debat om Lundbeck.Jeg er overbevist om, at den får et gevaldigt l..
5
15 jan
LUN
Lundbeck-aktien er i nedtrend for 50-dages glidende gennemsnit ligger under 200-dages glidende genne..
4
15 jan
LUN
Ikke helt ved siden af, men den er simpelthen for kedelig for den typiske kortsigtede adrenalinsøgen..
3
15 jan
LUN
@Baunsgaard Jeg kiggede lige hurtigt paa Lundbeck. Deres operating expenses var ekstremt hoeje i 201..
1
15 jan
LUN
@MatthewDK Tak for en fornuftig oversigt og et godt grin. @Baunsgaard Jeg ville ikke selv koebe en v..
1

Novo Nordisk/Goldman: Diabetestablet vil få den høje vækst tilbage

19-01-2018 15:11:36
Novo Nordisk står med et meget stærkt kort på hånden, hvis selskabet får en tabletudgave af det store væksthåb Ozempic (Semaglutid) godkendt og sendt på markedet.Det mener den amerikanske investeringsbank Goldman Sachs, der vurderer, at investorerne på aktiemarkedet ikke har taget tilstrækkeligt højde for de store muligheder for diabetesmidlet.Derfor har banken hævet sit kursmål for Novo Nordisk-a..

WDH/SEB: Amerikansk høreapparatmarked vokser mere end ventet

19-01-2018 14:35:39
Der var mere fart på den private del af det amerikanske høreapparatmarked i slutningen af 2017, end den svenske bank SEB havde ventet.Det skriver Bloomberg News på baggrund af en analyse fra SEB.Den private del af det amerikanske høreapparatmarked voksede 7,3 pct. i fjerde kvartal mod 2,8 pct. i tredje kvartal ifølge tal fra American Hearing Aid Association. Det var højere, end SEB har ventet, og ..

Aktier/åbning: Børshuse skubber Chr. Hansen og Novo til tops

19-01-2018 09:23:02
Chr. Hansen og Novo Nordisk er strøget til tops på det danske aktiemarked og medvirker til at hive det danske C25-indeks i et solidt plus fredag morgen.Stemningen var ellers svagt negativ i futuremarkedet indtil kort før åbningen.C25-indekset stiger 0,5 pct. til 1160,09 og ligger til et samlet plus på 0,8 pct. i denne uge.Især Chr. Hansen er sprunget i vejret fra åbningen. Aktien stiger 3,9 pct. t..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo Nordisk/Goldman: Diabetestablet vil få den høje vækst tilbage
2
Nordea forbyder flere tusinde ansatte at handle med bitcoin - citat
3
Fredagens aktier: William Demant tog føringen i positivt marked
4
SEB falder på børsen efter milliardnedskrivning
5
SIF sælger Robert Skov til FC København - NY

Relaterede aktiekurser

Lundbeck A/S 316,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. januar 2018 14:00:22
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180112.1 - EUROWEB4 - 2018-01-20 14:00:22 - 2018-01-20 14:00:22 - 1 - Website: OKAY